Gamida Cell Ltd (GMDAQ)

[midastouch017]

Gamida Cell delay does not impact peak sales, says Piper Sandler Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Gamida Cell with a $13 price target after the FDA requested additional manufacturing data on omidubicel. Gamida Cell now anticipates completing the full biologics license application submission in the second half of 2021 versus prior guidance of mid-2021, Tenthoff tells investors in a research note. The analyst now anticipates Gamida could launch omidubicel later in 2022 than previously anticipated, which lowers his revenue forecast to $25M from prior $41M
However, the few month delay does not impact his peak revenue estimate or price target.

https://thefly.com/landingPageNews.php?id=3212494&headline=GMDA-Gamida-Cell-delay-does-not-impact-peak-sales-says-Piper-Sandler